Compile Data Set for Download or QSAR
Report error Found 30 Enz. Inhib. hit(s) with all data for entry = 10341
TargetTGF-beta receptor type-1(Human)
Agomab Spain S.L.U.

US Patent
LigandChemical structure of BindingDB Monomer ID 63223BDBM63223(2-(piperazin-1-yl)ethyl 3-fluoro-5-(2-(3-(6-methyl...)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2026
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Agomab Spain S.L.U.

US Patent
LigandChemical structure of BindingDB Monomer ID 63218BDBM63218(2-(methylamino)ethyl 3-fluoro-5-(2-(3-(6-methylpyr...)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2026
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Agomab Spain S.L.U.

US Patent
LigandChemical structure of BindingDB Monomer ID 63211BDBM63211((1-methylpiperidin-4-yl)methyl 3-fluoro-5-(2-(3-(6...)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2026
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Agomab Spain S.L.U.

US Patent
LigandChemical structure of BindingDB Monomer ID 63206BDBM63206(2-(diethylamino)ethyl 3-fluoro-5-(2-(3-(6-methylpy...)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2026
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Agomab Spain S.L.U.

US Patent
LigandChemical structure of BindingDB Monomer ID 63205BDBM63205(2-(4-methylpiperazin-1-yl)ethyl 3-fluoro-5-(2-(3-(...)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2026
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Agomab Spain S.L.U.

US Patent
LigandChemical structure of BindingDB Monomer ID 63202BDBM63202(2-(dimethylamino)ethyl 5-(2-(3-(6-methylpyridin-2-...)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2026
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Agomab Spain S.L.U.

US Patent
LigandChemical structure of BindingDB Monomer ID 63199BDBM63199(2-morpholinoethyl 3-fluoro-5-(2-(3-(6-methylpyridi...)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2026
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Agomab Spain S.L.U.

US Patent
LigandChemical structure of BindingDB Monomer ID 63196BDBM63196(2-(dimethylamino)ethyl 3-fluoro-5-(2-(3-(6-methylp...)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2026
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Agomab Spain S.L.U.

US Patent
LigandChemical structure of BindingDB Monomer ID 63225BDBM63225(piperidin-4-yl 3-fluoro-5-(2-(3-(6-methylpyridin-2...)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2026
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Agomab Spain S.L.U.

US Patent
LigandChemical structure of BindingDB Monomer ID 63224BDBM63224(piperidin-4-ylmethyl 3-fluoro-5-(2-(3-(6-methylpyr...)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2026
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Agomab Spain S.L.U.

US Patent
LigandChemical structure of BindingDB Monomer ID 63223BDBM63223(2-(piperazin-1-yl)ethyl 3-fluoro-5-(2-(3-(6-methyl...)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2026
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Agomab Spain S.L.U.

US Patent
LigandChemical structure of BindingDB Monomer ID 63222BDBM63222(2-(isopropylamino)ethyl 3-fluoro-5-(2-(3-(6-methyl...)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2026
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Agomab Spain S.L.U.

US Patent
LigandChemical structure of BindingDB Monomer ID 63220BDBM63220(2-(ethylamino)ethyl 3-fluoro-5-(2-(3-(6-methylpyri...)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2026
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Agomab Spain S.L.U.

US Patent
LigandChemical structure of BindingDB Monomer ID 63219BDBM63219(2-aminoethyl 3-fluoro-5-(2-(3-(6-methylpyridin-2-y...)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2026
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Agomab Spain S.L.U.

US Patent
LigandChemical structure of BindingDB Monomer ID 63218BDBM63218(2-(methylamino)ethyl 3-fluoro-5-(2-(3-(6-methylpyr...)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2026
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Agomab Spain S.L.U.

US Patent
LigandChemical structure of BindingDB Monomer ID 63216BDBM63216(2-(aziridin-1-yl)ethyl 3-fluoro-5-(2-(3-(6-methylp...)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2026
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Agomab Spain S.L.U.

US Patent
LigandChemical structure of BindingDB Monomer ID 63225BDBM63225(piperidin-4-yl 3-fluoro-5-(2-(3-(6-methylpyridin-2...)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2026
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Agomab Spain S.L.U.

US Patent
LigandChemical structure of BindingDB Monomer ID 63215BDBM63215(2-(azetidin-1-yl)ethyl 3-fluoro-5-(2-(3-(6-methylp...)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2026
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Agomab Spain S.L.U.

US Patent
LigandChemical structure of BindingDB Monomer ID 63214BDBM63214(quinuclidin-4-yl 3-fluoro-5-(2-(3-(6-methylpyridin...)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2026
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Agomab Spain S.L.U.

US Patent
LigandChemical structure of BindingDB Monomer ID 63213BDBM63213((S)-quinuclidin-3-yl 3-fluoro-5-(2-(3-(6-methylpyr...)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2026
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Agomab Spain S.L.U.

US Patent
LigandChemical structure of BindingDB Monomer ID 63212BDBM63212((R)-quinuclidin-3-yl 3-fluoro-5-(2-(3-(6-methylpyr...)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2026
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Agomab Spain S.L.U.

US Patent
LigandChemical structure of BindingDB Monomer ID 63211BDBM63211((1-methylpiperidin-4-yl)methyl 3-fluoro-5-(2-(3-(6...)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2026
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Agomab Spain S.L.U.

US Patent
LigandChemical structure of BindingDB Monomer ID 63208BDBM63208(1-methylpiperidin-4-yl 3-fluoro-5-(2-(3-(6-methylp...)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2026
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Agomab Spain S.L.U.

US Patent
LigandChemical structure of BindingDB Monomer ID 63206BDBM63206(2-(diethylamino)ethyl 3-fluoro-5-(2-(3-(6-methylpy...)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2026
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Agomab Spain S.L.U.

US Patent
LigandChemical structure of BindingDB Monomer ID 63205BDBM63205(2-(4-methylpiperazin-1-yl)ethyl 3-fluoro-5-(2-(3-(...)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2026
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Agomab Spain S.L.U.

US Patent
LigandChemical structure of BindingDB Monomer ID 63202BDBM63202(2-(dimethylamino)ethyl 5-(2-(3-(6-methylpyridin-2-...)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2026
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Agomab Spain S.L.U.

US Patent
LigandChemical structure of BindingDB Monomer ID 63199BDBM63199(2-morpholinoethyl 3-fluoro-5-(2-(3-(6-methylpyridi...)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2026
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Agomab Spain S.L.U.

US Patent
LigandChemical structure of BindingDB Monomer ID 63198BDBM63198(2-(dimethylamino)ethyl 6-(2-(3-(6-methylpyridin-2-...)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2026
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Agomab Spain S.L.U.

US Patent
LigandChemical structure of BindingDB Monomer ID 63197BDBM63197(2-(dimethylamino)ethyl 5-(2-(3-(6-methylpyridin-2-...)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2026
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
Agomab Spain S.L.U.

US Patent
LigandChemical structure of BindingDB Monomer ID 63196BDBM63196(2-(dimethylamino)ethyl 3-fluoro-5-(2-(3-(6-methylp...)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/27/2026
Entry Details
US Patent